Aims The prognostic implication of adiposity on clinical outcomes in atrial fibrillation (AF)
patients treated with oral anticoagulation is unclear. Methods and results A total of 17 913 …

Background: The current status and outcomes of direct oral anticoagulant (DOAC) use have
not been widely evaluated in unselected patients with atrial fibrillation (AF) in the real world …

This ARISTOPHANES analysis examined stroke/systemic embolism (SE) and major
bleeding (MB) among a subgroup of nonvalvular atrial fibrillation (NVAF) patients with …

Background Inappropriate doses of direct oral anticoagulants (DOACs) are often prescribed.
This study evaluated the prevalence, outcomes, and predictors of the prescription of …

Older patients with atrial fibrillation (AF) are at higher risk of thromboembolic events and oral
anticoagulant (OAC)-related bleeding complications. This meta-analysis evaluates the …

Direct Oral Anticoagulants (DOACs) require dose adjustment based on specific patient
characteristics, making them prone to incorrect dosing. The current study aimed to evaluate …

In 2016, the International Society on Thrombosis and Haemostasis (ISTH) published
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …

Objective To determine the association between direct oral anticoagulant (DOAC) use and
risk of major adverse cardiac events (MACEs) in patients with atrial fibrillation (AF). Patients …

Background: Guidelines caution against the use of non–vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …

Background—Oral anticoagulants such as apixaban, dabigatran, and rivaroxaban are
alternatives to warfarin for preventing events in patients with atrial fibrillation. Direct …